Press Release Archives

  Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients   No dose-limiting toxicities or significant treatment-related adverse events were observed for any patient at any dose level       August 1, 2022   WARREN, N.J.–(BUSINESS WIRE)–Tevogen Bio,Continue reading “Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment”

  Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D   Acclaimed oncologist and immunotherapy expert Neal Flomenberg, M.D. joins Tevogen Bio as Chief Scientific Officer (CSO) and Global Head of Research & Development   Dr. Flomenberg most recently served as Professor and ChairmanContinue reading “Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D”

  Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology   Tevogen Bio’s new Research and Development Center is located in Philadelphia’s Wanamaker Office Building Strategic location of the R&D Center compliments Tevogen’s research facility at CIC Philadelphia as the company expands its precision T cell product pipeline inContinue reading “Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology”

  Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board   Tevogen’s Corporate Advisory Board represents renowned experts from all sectors of the healthcare system, academia, financial industry, and patient advocates to provide guidance as the company continues to expand its genetically unmodified precision TContinue reading “Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board”

  Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients   Trial has advanced to the fourth and final dose escalation cohort with no dose-limiting toxicities observed to-date   Tevogen’s investigational T cell product is genetically unmodified and target-specific   The enrollment is expectedContinue reading “Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients”

  Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio   Tevogen Bio’s new facilities at CIC Philadelphia will expand the company’s research and development capabilities and will accelerate the advancement of its product pipeline.   Tevogen’s scientists, technicians, and engineers will use the space to help simultaneouslyContinue reading “Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio”

  Tevogen Bio Expands Executive Leadership Team to Accelerate Operational Growth and Commercial Readiness   New Chief Technical Officer, Stephen Chen, and Global Commercial Lead, Sadiq Khan will support the company’s rapid operational growth and commercialization readiness   Tevogen’s Executive Leadership Team is comprised of experts across cell and gene therapeutic disciplines to accelerate theContinue reading “Tevogen Bio Expands Executive Leadership Team to Accelerate Operational Growth and Commercial Readiness”

  Tevogen Bio™ Appoints Prominent Industry Leader Susan Podlogar to the Company’s Corporate Advisory Board   Tevogen’s Corporate Advisory Board represents distinguished industry leaders, policy experts, and patient advocates to provide guidance as the company continues to expand its next generation Precision T cell Platform Technology   MetLife’s Chief Human Resources Officer Susan Podlogar appointedContinue reading “Tevogen Bio™ Appoints Prominent Industry Leader Susan Podlogar to the Company’s Corporate Advisory Board”

  Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations   NJ’s well established Biopharma infrastructure and highly skilled workforce will facilitate Tevogen’s growth   The dynamic medical innovation ecosystem of NJ offers significant opportunities to collaborate   Proximity to world-class global transportation hub and Tevogen’s R&D facilities will add furtherContinue reading “Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations”

  Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis   January 20, 2022     METUCHEN, N.J.–(BUSINESS WIRE)–Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced its intention to study its proprietary off-the-shelf T cellContinue reading “Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis”